Genmab — Februar 2021
-
to rub it in, Novartis and the Gates Foundation are joining forces to discover and develop a gene therapy to cure sickle cell disease https://www.statnews.com/2021/02/17/novartis-gates-foundation-aim-to-create-more-practical-sickle-cell-gene-therapy/
-
That may be the future - gene therapy or manipulation which lead the present value adjustment today/yesterday?
-
I wasn
-
was not looking for 1 to 1 connect. in that term. But it seems like people forget the risk and then having a wakeup call suddenly which also w
ill affect peers -
should be brief. As you mention Genmab has a broad foundation that has been recognized by value in the market
-
God morgen.
-
Asien: Usikkerhed får investorerne til at hente gevinster hjem - NY
https://www.proinvestor.com/investornyt/672258/asien-usikkerhed-far-investorerne-til-at-hente-gevinster-hjem-ny -
Torsdagens aviser med Mærsk, Topdanmark og MT Højgaard:
https://www.proinvestor.com/investornyt/672255/torsdagens-aviser-med-maersk-topdanmark-og-mt-hojgaard -
Looking for new immuno Therapeutics in RRMM https://www.onclive.com/view/looking-to-novel-immunotherapeutics-in-relapsed-refractory-multiple-myeloma
-
Genmab is excited to present at #JSMO2021. Japanese Society of Medical Oncology Management. https://twitter.com/Genmab/status/1362190140735709184
-
"In addition to cancer, we may consider partnership opportunities to address any disease area where antibody-based therapies may be effective, including autoimmune conditions, inflammation, central nervous system conditions and infectious diseases." i wonder if this statement is meant only for partnerships or if Genmab wants to expand their horizon themselves https://www.genmab.com/partnering/#page-approach
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/91112_genmab_feb_18.JPG Genmab holder sig fint omkring den opadgående midterlinie og kurs 3000 ser stadig realistisk ud inden for kommende 8-10 mdr
-
Nature, Blood cancer journal - Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment https://www.nature.com/articles/s41408-021-00430-6
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind